The 2020-2021 CDP application cycle will open in the summer of 2020. Please return to this page at that time for updates.
See the Guidelines & Instructions for each award category listed in the sections below.
Policies & Procedures (update coming soon)
- The Leukemia & Lymphoma Society is implementing a new rule regarding overlapping aims in grant proposals submitted to LLS. This policy applies to proposals submitted within the same application cycle, which is defined as all LLS calls for proposals – across all grant programs – that open within the same calendar year. An application to any LLS grant program may not have aims that substantially overlap with the aims of any other application (either to the same program or to a different program) that includes the same investigator(s) as PI(s), Co-I(s), Project or Core Leaders, or collaborator(s). All such duplicate grant proposal submissions with substantially overlapping aims are subject to administrative disqualification, and such proposals will not be reviewed further or considered for funding. Contact firstname.lastname@example.org with any questions about this policy or to discuss with LLS scientific staff any questions concerning potential overlap between applications.
- Applicants who previously held a career development-type award of any amount and duration are now eligible to apply for a CDP award. Continuing with recent policy, applicants who currently hold a career development-type award that is lower in total CDP award amount are allowed to apply and hold both awards, where applicable. The continuing exception to this rule is K99 awardees, who are able to apply for a CDP award and simultaneously hold a K99 and CDP award.
- Scholar awards for those funded in this cycle has increased to $120,000 per year (from $110,000 per year).
- In 2019, The Leukemia & Lymphoma Society will be awarding CDP Achievement Awards to principal investigators of awards ending in 2019 with the most impactful LLS-acknowledged publication or presentation. We anticipate that this award mechanism will continue beyond 2019. See the Guidelines & Instructions for details.
Breif descriptions of each category are provided below. Please refer to the Eligibility Outline in the next section or the Guidelines & Instructions for each category to determine which category is most appropriate for your application.
Award: $120,000 per year for five years
Requirements: The Scholar award supports rising stars in the blood cancer research field. You must be a highly qualified investigator who has shown a capacity for independent, sustained, original investigation in the field of hematologic malignancies. You should hold an independent faculty-level position and should have obtained substantial support for your research from a national agency.
Scholar in Clinical Research
Award: $125,000 per year for five years
Eligibility was recently expanded to include any permanent, independent, clinical faculty who are not on a laboratory-based, tenure-track career path (those with tenure-track positions are still eligible). The research support requirement is expanded to include funding from any source that adequately supports the research. Protected time for research is now defined to be in the range of 20-40%. Some of the award may be used for salaries of other personnel who are directly connected with the clinical research activities of the applicant.
**Please refer to the Guidelines & Instructions for more details regarding changes to the eligibility criteria if applying to this sub-program.
Requirements: You must be a highly qualified investigator who holds an independent faculty-level appointment and is conducting original, independent applied research, often involving early-stage clinical trials that will advance the prevention, diagnosis or treatment of hematologic malignancies. The research should be related to your clinical activities, and must involve patients. You're expected to have concomitant support for your research from another source or agency.
Investigators who are primarily laboratory-based, and/or who are working on primarily blood cancer model systems rather than patients, are not eligible for the Scholar in Clinical Research Award, and should consider the Scholar Award.
Award: $67,000 per year for two or three years
Requirements: You must be a highly qualified postdoctoral fellow or instructor who's completed a minimum of 2.5 years of postdoctoral research training and is in a mentored research position, continuing a research program of direct relevance to hematological malignancies and/or relevant pre-malignant conditions. In addition, your Sponsor(s) must be have the appropriate experience to mentor you as you engage in blood cancer-relevant research. This award provides you with the opportunity to continue building a research program that will make you competitive for an independent position by the end of the award funding period.
Note: The Special Fellow in Clinical Research sub-program will not run this year.
Award: $60,000 per year for three years
Requirements: You must be a promising investigator with less than 2.5 years of postdoctoral research training. This award encourages you to embark on an academic career involving basic or translational research in hematologic malignancies and/or relevant premalignant conditions under a research sponsor's direction. The proposal must be directly relevant to hematological malignancies and/or relevant pre-malignant conditions. In addition, your Sponsor(s) must be have the appropriate experience to mentor you as you engage in research of direct relevance to blood cancer.
Eligibility Outline for 2019-2020 Application Cycle
|Scholar||Scholar in Clinical Research||Special Fellow (2-year)||Special Fellow (3-year)||Fellow|
MD, PhD, DVM, or equivalent
MD, PhD, DVM, or equivalent
MD, PhD, DVM, or equivalent
MD, PhD, DVM, or equivalent
MD, PhD, DVM, or equivalent
|Oral thesis defense date**||N/A||N/A||
On or after June 30, 2015
On or after June 30, 2016
On or after June 30, 2017
|Independent faculty position required?***||Yes||Yes||No||No||No|
|Earliest start date of independent position***||On or after January 1, 2012||
On or after January 1, 2010
|Most recent start date||January 1, 2018||N/A||N/A||N/A||N/A|
|Applicant R01-level funding required?****||Yes||No*****||No||No||No|
|Sponsor R01-level funding required?****||N/A||N/A||Yes||Yes||Yes|
*For Fellows, the degree must be conferred by the Award start date.
**More details are contained in the Guidelines & Instructions
***Mentored faculty positions (e.g. Instructor) do not count as independent
****Substantial, peer-reviewed funding that extends beyond the Award start date; must be the principal investigator on this funding
*****Funding may come from any source; see the Guidelines & Instructions for more details
2019-2020 Application Timeline
Please note that in the event that an application deadline falls on a weekend or U.S. holiday, the deadline will be enfored at 3:00 PM (ET) on the business day immediately following the listed deadline.
|Eligibility Phase Open||May 1, 2019|
September 1, 2019, 3:00 PM (Eastern Daylight Time)
|Eligibility determination by LLS staff||Rolling: May through September 8, 2019|
|Notification of eligibility||By September 8, 2019 (typically within 2 business days after submission)|
|Abstract Phase Open||Immediately after eligibility approval|
|Abstracts Due||September 13, 2019, 3:00 PM (Eastern Daylight Time)|
|Full Application Phase Open||Immediately after Abstract Phase submission|
|Reference Letters Due||September 27, 2019, 3:00 PM (Eastern Daylight Time)|
|Full Applications Due||
September 27, 2019, 3:00 PM (Eastern Daylight Time)
|Panel Review Meeting||January 2020|
|Final Version of Lay Abstract Due||May 1, 2020|
|Award Start Date||July 1, 2020|
How to Apply
The CDP application will be completed in 3 phases: Eligibility, Abstracts, and Full Application. Below are step-by-step instructions for applying:
- Use the Eligibility Outline chart on this page to determine which award category is right for you.
- Download and read the Guidelines & Instructions for your award category (linked in each category section above).
- Log in to the LLS Research Portal (FLUXX) and select Career Development Program. Click "Apply to CDP!" to begin the application process.
If you need a new account or need to reset your password for an existing account, contact email@example.com. Please do this well in advance of the first deadline.
- Follow the instructions on the LLS Research Portal and in the Guidelines & Instructions to complete your Eligibility submission. Please note that this year's Eligibility requirements include completion of 1) a brief online form and 2) an uploaded document. Fellow and Special Fellow applicants must have this document signed by their sponsors.
- LLS staff will determine eligibility on a rolling basis using the criteria described in the Guidelines & Instructions.
You may be contacted by an LLS staff member if more information is needed for your eligibility submission. If this occurs, LLS will accept one submission in addition to the original.
- You will receive an email notifying you of your Eligibility approval status. Once your Eligibility is approved, return to the LLS Research Portal, select "New or Pending" under Requests on the left panel and follow the instructions on this site and in the Guidelines & Instructions to begin the Abstract phase of the application.
- Once you have submitted your Abstract, you may immediately begin your Full Application. Carefully follow the instructions on the LLS Research Portal and Guidelines & Instructions. Full Applications require completion of both the online form and the current application template, which should be downloaded from the Project Document section of the LLS Research Portal.
Failure to follow all application instructions may result in administrative triage of your application.
- As part of the Full Application document, you will be asked to assign your project and each aim a Recommended Mission Score. See the Mission Score section below or in the guidelines of your award category for more information.
- Request letters of reference well in advance of the Full Application deadline.
It is the applicant's responsibility to ensure that all letters of reference are received by LLS by the full application deadline.
- Submit your Full Application to LLS prior to the Full Application deadline. We strongly recommend submitting at least 1 week in advance of the deadline, as site traffic on the day of and days leading up to the deadline will be heavy.
Carefully check every page of your application prior to submission. The applicant is ultimately responsible for this submission, even if someone else submits it on the applicant's behalf.
At any time during the application process, including after submitting your Full Application, you can check the status of your application by logging in to the LLS Research Portal, selecting your application (under Requests in either “New or Pending” or “Submitted”) and referring to the Status in the yellow box at the top of the page.
If you have any technical difficulties with the LLS Research Portal, please contact firstname.lastname@example.org.
Before applications are assigned a Priority Score, each receives a Mission Score to measure adherence of the application to LLS’s Mission of curing blood cancer. CDP Awards must focus on those questions of direct relevance to blood cancer, which may include questions of normal blood biology. Research on normal blood biology must have a clear relevance to blood cancer. The Mission Score will be assigned based on the overall focus of the application. For example, if most of the aims are focused on established cell lines but there is a sentence or two describing how results will be verified in patient samples, the Mission Score will be 2.
Proposals that do not have clear relevance to blood cancer will be triaged without full review.
Mission Score of 1: The experimental plan must address mechanisms directly relevant to the pathogenesis, diagnosis, or treatment of hematologic malignancies and/or relevant premalignant conditions/states. In addition, at least some experiments must include patients, patient materials, or the most appropriate animal model system.
Mission Score of 2: The experimental plan must address mechanisms directly relevant to the pathogenesis, diagnosis, or treatment of hematologic malignancies and/or relevant premalignant conditions/states. In addition, at least some experiments must use cell lines and/or animal models that are directly relevant to hematologic malignancies and/or relevant premalignant conditions/states.
Mission Score of 3: The experimental plan must address basic mechanisms directly relevant to normal blood cell development, hematopoietic stem/precursor cell function, or immune responses. These studies must have clear relevance to blood cancer and must use appropriate models to understand these mechanisms in blood cells.
Mission Score of 4: Does not address mechanisms directly relevant to normal blood cell development/function, hematologic malignancies and/or relevant premalignant conditions/states.
Applications with a Mission Score of 4 will not reach the full review committee.
Frequently Asked Questions
Need More Information?
Contact email@example.com with any questions not addressed on this page, the program guidelines, Policies & Procedures, or the above FAQ.